Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC90 of remifentanil with ciprofol or propofol for suppression of tracheal intubation response
ChiCTR2300078275Phase 4Not yet recruiting
- Sponsor
- The Affiliated Heping Hospital of Changzhi Medical College
- Start
- Dec 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remifentanil, ciprofol and propofol in intubation (4 arms), sponsored by The Affiliated Heping Hospital of Changzhi Medical College. Primary endpoint: EC90 of remifentanil to inhibit tracheal intubation response. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
remifentanilciprofolpropofol
03
Conditions
intubation
Beyond the preview
Go deeper on ChiCTR2300078275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078275.